Mahnaz Nazari
1,2 
, Ehsan Javandoost
3, Mehdi Talebi
1,4, Aliakbar Movassaghpour
1*, Masoud Soleimani
3* 1 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
4 Department of Applied Cell Sciences, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Introduction
*Corresponding Authors: *Corresponding Authors: Aliakbar Movassaghpour and Masoud Soleimani, Tel: 98 41 33343888, Fax: 98 41 33373894 , Email:, Tel & Fax: 98 21 82884508, Email: soleim_m@modares.ac.ir, Email:
movassaghpour@ gmail.com; *Corresponding Authors: Aliakbar Movassaghpour and Masoud Soleimani, Tel: 98 41 33343888, Fax: 98 41 33373894 , Email: movassaghpour@ gmail.com, Tel & Fax: 98 21 82884508, Email: , Email:
soleim_m@modares.ac.ir
Abstract
Platelet-derived microparticles (PMPs) are a group of micrometer-scale extracellular vesicles released by platelets upon activation that are responsible for the majority of microvesicles found in plasma. PMPs’ physiological properties and functions have long been investigated by researchers. In this regard, a noticeable area of studies has been devoted to evaluating the potential roles and effects of PMPs on cancer progression. Clinical and experimental evidence conflictingly implicates supportive and suppressive functions for PMPs regarding cancer. Many of these functions could be deemed as a cornerstone for future considerations of PMPs usage in cancer targeted therapy. This review discusses what is currently known about PMPs and provides insights for new and possible research directions for further grasping the intricate interplay between PMPs and cancer.